{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:43:25Z","timestamp":1792514605387,"version":"4.5.0"},"reference-count":8,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T00:00:00Z","timestamp":1678147200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Dermatology"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Biological drugs, including IL\u201017A inhibitors, have become the first\u2010line treating options for moderate to severe psoriasis, and reports show a beneficial effect of IL\u201017A inhibitors on bullous pemphigoid. Here, we report two cases of bullous pemphigoid in remission that experienced severe flares during treatment with two major IL\u201017A inhibitors, i.e., ixekizumab or secukinumab for their psoriasis vulgaris. The patient with bullous pemphigoid induced by secukinumab became very recalcitrant to control the relapse. This is by far the first and paradoxical report on the IL\u201017A inhibitors having a negative effect on bullous pemphigoid patients in previously stable status. Our reports of these two cases alert clinicians to be careful when using IL\u201017A in pemphigoid patients. We also suggest that patients with psoriasis vulgaris should be asked for a detailed history of pemphigoid and its BP180 autoantibodies status be checked before using these biologicals.<\/jats:p>","DOI":"10.1111\/1346-8138.16765","type":"journal-article","created":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T09:08:21Z","timestamp":1678180101000},"page":"956-959","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Two cases with bullous pemphigoid relapsed after using <scp>interleukin\u201017A<\/scp> inhibitors for psoriasis: A paradoxical reaction"],"prefix":"10.1111","volume":"50","author":[{"given":"Rui","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Dermatology Peking University First Hospital  Beijing China"},{"name":"National Clinical Research Center for Skin and Immune Diseases  Beijing China"},{"name":"Beijing Key Laboratory of Molecular Diagnosis on Dermatoses  Beijing China"},{"name":"NMPA Key Laboratory for Quality Control and Evaluation of Cosmetics  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiping","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Dermatology Peking University First Hospital  Beijing China"},{"name":"National Clinical Research Center for Skin and Immune Diseases  Beijing China"},{"name":"Beijing Key Laboratory of Molecular Diagnosis on Dermatoses  Beijing China"},{"name":"NMPA Key Laboratory for Quality Control and Evaluation of Cosmetics  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8317-3414","authenticated-orcid":false,"given":"Mingyue","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Dermatology Peking University First Hospital  Beijing China"},{"name":"National Clinical Research Center for Skin and Immune Diseases  Beijing China"},{"name":"Beijing Key Laboratory of Molecular Diagnosis on Dermatoses  Beijing China"},{"name":"NMPA Key Laboratory for Quality Control and Evaluation of Cosmetics  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,3,7]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2018.09.003"},{"key":"e_1_2_9_3_1","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1111\/ddg.14291","article-title":"Adjuvant treatment with secukinumab induced long term remission in a patient with severe bullous pemphigoid","volume":"18","author":"Holtsche MM","year":"2020","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14760"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16189"},{"key":"e_1_2_9_6_1","first-page":"e76","article-title":"Ixekizumab successfully treated refractory psoriasis concurrent bullous pemphigoid","volume":"50","author":"Xiao Y","year":"2022","journal-title":"J Dermatol"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61140-4"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/08820139.2020.1832113"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2022.2089331"}],"container-title":["The Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.16765","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1346-8138.16765","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.16765","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T17:24:54Z","timestamp":1692465894000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1346-8138.16765"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,7]]},"references-count":8,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["10.1111\/1346-8138.16765"],"URL":"https:\/\/doi.org\/10.1111\/1346-8138.16765","archive":["Portico"],"relation":{},"ISSN":["0385-2407","1346-8138"],"issn-type":[{"value":"0385-2407","type":"print"},{"value":"1346-8138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,7]]},"assertion":[{"value":"2022-12-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}